About Retrogenix
Retrogenix is a Healthcare company based in Whaley Bridge (United Kingdom) founded in 2008, and was acquired by Charles River Laboratories in March 2021. Developing specialist cell microarray technology for membrane target deconvolution and receptor identification. Retrogenix offers products and services including Cell Microarray Technology, Hit Validation Services, and Bioinformatic Analysis. Its focus areas include Life Sciences, Life Sciences Platforms and Tools, Research Assays and Cell Based Assays.
Company details
Retrogenix is developing specialist cell microarray technology to screen drugs against human proteins. The technology can be used to rapidly identify the human cell surface receptors of antibodies, proteins, viruses and small molecules, thereby determining their primary target and secondary target (off-target) activities. Microarrays of over 4,500 plasma membrane proteins expressed in human cells allow physiologically relevant interactions with test molecules or protein ligands to be identified with high sensitivity and specificity. The companys technology is also used by global pharmaceutical companies to advance drug discovery and development, predominantly in biologics research.
- Headquarters Whaley Bridge, United Kingdom
- Stage Acquired
- SectorsHealthcare
- Email••••••••
- Phone•••• ••••
- Website retrogenix.com
- Social LinkedIn
- Acquired by Charles River Laboratories (Mar 2021)
- Investors
- Acquired byCharles River Laboratories
(Mar 2021)
Products & Services of Retrogenix
Retrogenix offers a comprehensive portfolio of products and services, including Cell Microarray Technology, Hit Validation Services, and Bioinformatic Analysis.
Identifies ligand-receptor interactions for drug development.
Confirms protein binding through flow cytometry.
Analyzes screening data for drug discovery insights.
Investors in Retrogenix
Retrogenix has secured backing from 1 investor, including institutional investors. Prominent investors backing the company include Charles River Laboratories.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Provider of drug discovery and preclinical development services | 1947 | criver.com | Wilmington, United States |
Investor details for Retrogenix
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Timeline of Retrogenix
2 dated milestones of Retrogenix across 13 years, from founding to its latest funding, stage changes and deals.
- Founded Retrogenix is founded.
- Exit Acquired by Charles River Laboratories.
Top companies in Life Sciences Platforms & Tools
3 companies that operate in the same segment as Retrogenix (Life Sciences Platforms & Tools) in United Kingdom, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Nanopore-based electronic systems for single-molecule analysis are developed. | 2005 | Oxford, Oxfordshire, United Kingdom | USD 1.34 B | USD 301.49 M | 1,372 | |
Genetically modified cell lines are developed using AAV gene-editing platform. | 2007 | Cambridge, Cambridgeshire, United Kingdom | USD 46.29 M | |||
Biological reagents and antibodies are developed for life science research. | 1998 | Cambridge, Cambridgeshire, United Kingdom | USD 78.8 M |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Retrogenix
Complete news archive for Retrogenix
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Retrogenix
Retrogenix was founded in 2008.
Retrogenix is headquartered in Whaley Bridge, United Kingdom. It is registered at Whaley Bridge, Derbyshire, United Kingdom.
Retrogenix is developing specialist cell microarray technology to screen drugs against human proteins. The technology can be used to rapidly identify the human cell surface receptors of antibodies, proteins, viruses and small molecules, thereby determining their primary target and secondary target (off-target) activities. Microarrays of over 4,500 plasma membrane proteins expressed in human cells allow physiologically relevant interactions with test molecules or protein ligands to be identified with high sensitivity and specificity. The companys technology is also used by global pharmaceutical companies to advance drug discovery and development, predominantly in biologics research.
Retrogenix offers Cell Microarray Technology, Hit Validation Services, and Bioinformatic Analysis.
Retrogenix has 1 investor. Key investors include Charles River Laboratories.
Yes. Retrogenix was acquired by Charles River Laboratories in March 2021.